Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Key Takeaways:

• Genmab plans to submit an sBLA to the U.S. FDA.
• The submission is for a combination of Epcoritamab with Rituximab and Lenalidomide (R2).
• The therapy targets patients with relapsed or refractory follicular lymphoma (FL).
• Announcement made on May 1, 2025, from Copenhagen, Denmark.
• Potential to offer a new treatment option for difficult-to-treat lymphoma cases.

Genmab Advances Cancer Treatment with FDA Application

COPENHAGEN, Denmark—May 1, 2025—In a significant stride toward improving cancer therapies, biotechnology firm Genmab announced its intent to submit a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA). The application seeks approval for a combination treatment involving Epcoritamab plus Rituximab and Lenalidomide (R2) for patients battling relapsed or refractory follicular lymphoma (FL).

A Promising Combination Therapy

The proposed therapy merges Epcoritamab, an innovative antibody, with the established R2 regimen—Rituximab and Lenalidomide. This combination aims to enhance treatment efficacy for those whose FL has not responded to previous therapies or has returned after remission.

Addressing Relapsed/Refractory Follicular Lymphoma

Follicular lymphoma is a challenging form of non-Hodgkin lymphoma characterized by periods of remission and relapse. Patients with relapsed or refractory FL often have limited treatment options. Genmab’s initiative could potentially fill a critical gap in oncological care by offering a new line of defense against this persistent disease.

Navigating the Regulatory Pathway

Submitting an sBLA is a crucial step in bringing new treatments to market. FDA approval would not only validate the therapy’s efficacy and safety but also make it accessible to patients in need. Genmab’s announcement underscores the company’s commitment to advancing cancer treatment through rigorous scientific exploration and compliance with regulatory standards.

Potential Impact on Patients

If approved, this combination therapy could represent a meaningful advancement for patients facing the hardships of relapsed or refractory FL. It embodies hope for improved outcomes and quality of life, reinforcing the importance of continued innovation in cancer therapeutics.

Genmab’s Ongoing Commitment

As a leader in biotechnology, Genmab continues to pursue groundbreaking treatments. The company’s dedication to addressing unmet medical needs positions it at the forefront of developing next-generation cancer therapies.